U.S. FDA approves Takeda's lung cancer drug as second-line treatment

(Reuters) - Japan's Takeda Pharmaceutical Co Ltd said on Friday that the U.S. Food and Drug Administration approved its lung cancer drug, almost three months after the company acquired the drug's developer, Ariad Pharmaceuticals Inc.